In 2006, all indicators in the production and circulation fields of the pharmaceutical industry showed a year-on-year slowdown. However, the reporter got the sixth meeting of the Fourth Council of the China Chamber of Commerce for the Import and Export of Medicines and Health Products concluded on January 19. A good news: In 2006, China's foreign trade in pharmaceuticals and health products continued to grow rapidly at a high base. According to customs statistics, from January to November of 2006, the total import and export of medicines and health products in China reached US$27.811 billion, which represented a year-on-year increase of 20.72%, of which, the export value was US$17.807 billion, which was a year-on-year increase of 26.77%; the import amount was US$10.004 billion, With an increase of 11.26%, both imports and exports hit record highs. Due to the inertial growth at the end of the year, the total import and export volume of over 30 billion U.S. dollars is a foregone conclusion.
In the first 11 months of 2006, China’s foreign trade in pharmaceutical and healthcare products continued to maintain a large surplus, with export growth rate higher than that of imports by 15.51 percentage points, and the accumulated surplus amounted to 7.803 billion U.S. dollars. The trade surplus increased by 2.747 billion U.S. dollars over the same period of last year.
Many factors promote the rapid growth of foreign trade The relevant person in charge of the Chamber of Commerce for the Import and Export of Chinese Medicines and Health Products pointed out that the reason why China’s foreign trade in medicine and health products had such a high growth in 2006 was due to many factors.
First, the optimization of the macroeconomic environment worldwide, especially the continuous improvement of our economic environment. In 2006, the world economy grew steadily, the international market demand was strong, and China’s economy continued to maintain a strong growth. This led to strong external demand for Chinese medicines and health products, rapid increase in exports of medicines and health products, and continued growth in exports at a relatively high level; secondly, some countries Medical reform policies have been introduced in succession, such as "Management Measures for Large Medical Equipment Allocation and Use" and "Guidance on Formulating and Adjusting Inspection and Treatment Prices for Large-scale Medical Equipment", etc., to suppress the current high false inspection costs and blindly expand the scale of some medical institutions. The effect of this approach is obvious. The effects of the national macro-control measures have gradually emerged. The momentum of rapid growth in domestic investment has been curbed. Import growth has slowed down noticeably, with an increase rate of 7.28 percentage points lower than the same period of last year. Third, the domestic export tax rebate mechanism has been further adjusted and With the improvement of the issue of export tax reimbursement, the state of the company’s funds has been significantly improved, which has played a positive role in promoting the growth of China’s pharmaceutical and healthcare products exports. Fourth, the reform of the RMB exchange rate mechanism continues to deepen, and most companies are in procurement costs. Hesheng Costs work hard to reduce the cost rate as much as possible and continue to maintain a cost competitive advantage. Fifth, the diversification of foreign trade business entities, more and more companies are interested in developing foreign trade in medicine and health products, and companies are exploring the international market. Both power and pressure have been enhanced. Especially after the right to operate foreign trade has been liberalized, the long-term savings of private enterprises have been released, creating a huge export drive.
Highlights in various fields China's pharmaceutical products are fully involved in international trade and full exchange. Last year, China continued to fully participate in worldwide exchanges in pharmaceutical economy, technology, and trade. Chinese companies are increasingly participating in various international pharmaceutical and medical equipment exhibitions held around the world. The stronger. From January to November of 2006, China's pharmaceutical and health products exports to Asia, Europe, North America and other markets were respectively 7.139 billion U.S. dollars, 4.979 billion U.S. dollars and 3.816 billion U.S. dollars, up by 27.73%, 27.06%, and 20.71% respectively; The African and Latin American markets have achieved good results. Exports were 572 million U.S. dollars and 1.40 billion U.S. dollars, up 38.57% and 38.79% year-on-year, respectively; exports to the United States exceeded the 3 billion U.S. dollar mark for the first time, reaching 3.597 billion U.S. dollars. The year-on-year increase was 20.76%.
Chemical raw materials continue to maintain its advantages. China's chemical raw material medicines have the characteristics of large scale, low cost, and high output. The export value has always accounted for about 50% of China's total exports of pharmaceutical and health products, and it is the export pillar of China's pharmaceutical and health products industry. Last year, China continued to maintain its advantages in the traditional bulk chemical raw materials, especially antibiotics, vitamins, hormones, antipyretic analgesics, amino acids, alkaloids and other products continue to occupy a considerable share in the international pharmaceutical market. Some companies that have obtained US FDA certification and EU COS certificates have also performed better in the market, and export prices have also steadily increased, such as terramycin, griseofulvin, gentamycin sulfate, and some companies. Vermectin, caffeine, etc. From January to November of 2006, China's export of chemical raw materials was 9.632 billion U.S. dollars, an increase of 25.84% year-on-year, accounting for 54.09% of China's total exports of pharmaceutical and health products.
Grabbing imitation and commission processing gradually become a trend, a number of companies have access to Europe and the United States high-end market pass. In 2006, it was the peak period for many “bombshell†proprietary drugs with sales exceeding US$500 million. The non-patented drug market emerged in an unexpectedly high number, which also made the market for contract outsourcing production and outsourcing more demanding. This is a domestic enterprise. Bring new opportunities for development. Some domestic companies prepare for the expiration of patent drugs 3 to 5 years in advance, and rank among the top suppliers of generic drugs for the first time.
Chemicals exports have made breakthroughs. In 2006, two more companies in China had obtained cGMP certification from EU countries, resulting in five certified companies. Their pharmaceutical products can already be exported to the EU high-end market. In addition, there are two other companies that have signed cooperation agreements with U.S. companies to sell productions that meet the US FDA requirements to European and American markets. The pace of production companies entering the generic drug market has strongly promoted the export of chemical agents. From January to November 2006, the export value of chemical preparations in China was 456 million U.S. dollars, an increase of 24.37% year-on-year.
The deficit in medical device exports has been reversed. For a long time, China’s foreign trade in medical devices has presented a serious trade deficit, with imports exceeding exports. However, with the continuous improvement of China’s medical device production technology and product quality in recent years, the demand for imported medical devices has begun to slow down, and the import of medical devices has exceeded exports. The situation has been fundamentally reversed. According to customs statistics, from January to November 2006, China's medical device export volume was 6.265 billion U.S. dollars, an increase of 29.42% year-on-year, and the growth rate of exports was much higher than that of imports by 26.54 percentage points. The surplus amounted to 2.923 billion U.S. dollars, and it continued to expand.
From the perspective of export product structure, small and medium-sized products such as conventional equipment, surgical instruments, and massage instruments have price advantages, and their functions and reliability are comparable to those of similar foreign products. For example, thermometers produced in Shenzhen account for 70% of the world's total, and 80% of French and German dentures are made in China. Therefore, China's small and medium-sized medical devices have obvious comparative advantages and competitiveness in the international market. In the export of high-tech medical equipment, some private high-tech enterprises in China have developed rapidly in recent years. Ultrasound diagnostic instruments and patient monitors have independent intellectual property rights and independent brands.
Some companies' medical device products have obtained CE certification and ISO13485 system certification, and they have access to the international market and can enter more international markets. The ability of the international market to purchase these products is significantly higher than that of other products, and after the products have obtained CE certification, the standards have become higher, they have become guaranteed products, and prices have increased a lot. In particular, EU customers attach great importance to CE certification. CE certification products will soon be able to enter European and American sales channels, shortening the transaction cycle. The EU Dual Directives (WEEE and RoHS) have little impact on the export of these products. Many companies are already well prepared to conduct special training on upstream suppliers and the products can meet the requirements of the directive.
The export of Chinese medicine exceeded the one billion US dollar mark for the first time. From January to November 2006, China’s export volume of Chinese medicines was US$985 million. Based on the monthly average value, exports of Chinese medicines for the whole year of 2006 will exceed US$1.07 billion, exceeding the US$1 billion mark for the first time, and exports of all kinds of bulk medicinal materials are presented. Sharply rising trend. Despite the negative reports on traditional Chinese medicines in the European market and the imminent transition period stipulated in the EU's Traditional Herbal Registration Directive, with the continued recognition of Chinese medicine products by Europeans, Chinese medicine exports to Europe have shown rapid growth, especially Exports from France, the Netherlands, the United Kingdom and Spain increased by more than 40%, and the Netherlands reached 75.25%.
Coexistence of Opportunities and Challenges In 2007, the foreign trade of China's pharmaceutical and healthcare products will continue to maintain rapid growth. Chemical raw material medicine is the export pillar of China's pharmaceutical and health care products industry. Continued expansion of chemical raw material medicines in 2007 is an inevitable choice. China will continue to maintain its advantages in traditional bulk chemical raw material medicines, especially antibiotics, vitamins, hormones, and solutions. Thermal analgesics, amino acids, alkaloids and other products will continue to occupy a considerable share of the world.
While maintaining comparative advantages and competitiveness in the export of small and medium-sized medical devices, some high-tech medical equipment products and high value-added products will grow steadily, which will enable China's medical devices to have greater room for development in the international market. It is expected that the growth in the number and value of imported medical devices will continue to slow in 2007, and the prices of some imported medical devices will decline.
Exports of Chinese medicines will continue to maintain a good momentum of rapid growth, and exports of Chinese herbal medicines, decoction pieces, extracts and health products will continue to grow rapidly. Although the proportion of Chinese patent medicines representing the essence of traditional Chinese medicine is still relatively small, with the increase of national policy support and the accumulation of international experience, Chinese patent medicines will be a new growth point for Chinese medicine exports.
This year marks the sixth year of China’s accession to the WTO. To promote the advancement of science and technology in the pharmaceutical industry and enhance its international competitiveness, all ministries and commissions of the country will continue to introduce a series of policies to advance the system from the technical and regulatory levels in order to support the pharmaceutical companies to go global. Recently, the Ministry of Commerce awarded the China Chamber of Commerce for the Import and Export of Medicines and Health Products to set up an Export Commodity Technical Service Center. The center mainly studies the problems faced by international registration of enterprises and guides enterprises in the international registration of pharmaceuticals. This is to expand the export of medicines and health products in China. Will play an important role in promoting.
While optimistic expectations, some factors that affect export growth can not be ignored. The appreciation of the renminbi will weaken the competitiveness of Chinese medicine and health products in the international market. The increase in labor costs and raw material prices continue to rise sharply. The tight supply of coal, electricity, oil and transportation will affect the normal production and contractual performance of enterprises. Although trade protectionism is not the mainstream, trade friction problems have become increasingly prominent and the forms of friction have become increasingly diversified. In addition, the EU has introduced a series of related regulations such as EUP, which have increased the uncertainties in the export of Chinese medicine and health products.
At present, China’s foreign exchange reserves have exceeded one trillion U.S. dollars, and the macro environment has undergone fundamental changes. In accordance with the requirements of the Ministry of Commerce, lowering the trade surplus and adjusting the product mix will become the main tasks for the import and export of medical and health products this year.
In view of the high base in 2006, it also made it increasingly difficult for China's foreign trade in medical and health products to maintain rapid growth in 2007. It is expected that the import and export of Chinese medicine and health products will still be expected to maintain an increase of more than 15% in 2007, and the total import and export volume will exceed 350. One hundred million U.S. dollars.
In the first 11 months of 2006, China’s foreign trade in pharmaceutical and healthcare products continued to maintain a large surplus, with export growth rate higher than that of imports by 15.51 percentage points, and the accumulated surplus amounted to 7.803 billion U.S. dollars. The trade surplus increased by 2.747 billion U.S. dollars over the same period of last year.
Many factors promote the rapid growth of foreign trade The relevant person in charge of the Chamber of Commerce for the Import and Export of Chinese Medicines and Health Products pointed out that the reason why China’s foreign trade in medicine and health products had such a high growth in 2006 was due to many factors.
First, the optimization of the macroeconomic environment worldwide, especially the continuous improvement of our economic environment. In 2006, the world economy grew steadily, the international market demand was strong, and China’s economy continued to maintain a strong growth. This led to strong external demand for Chinese medicines and health products, rapid increase in exports of medicines and health products, and continued growth in exports at a relatively high level; secondly, some countries Medical reform policies have been introduced in succession, such as "Management Measures for Large Medical Equipment Allocation and Use" and "Guidance on Formulating and Adjusting Inspection and Treatment Prices for Large-scale Medical Equipment", etc., to suppress the current high false inspection costs and blindly expand the scale of some medical institutions. The effect of this approach is obvious. The effects of the national macro-control measures have gradually emerged. The momentum of rapid growth in domestic investment has been curbed. Import growth has slowed down noticeably, with an increase rate of 7.28 percentage points lower than the same period of last year. Third, the domestic export tax rebate mechanism has been further adjusted and With the improvement of the issue of export tax reimbursement, the state of the company’s funds has been significantly improved, which has played a positive role in promoting the growth of China’s pharmaceutical and healthcare products exports. Fourth, the reform of the RMB exchange rate mechanism continues to deepen, and most companies are in procurement costs. Hesheng Costs work hard to reduce the cost rate as much as possible and continue to maintain a cost competitive advantage. Fifth, the diversification of foreign trade business entities, more and more companies are interested in developing foreign trade in medicine and health products, and companies are exploring the international market. Both power and pressure have been enhanced. Especially after the right to operate foreign trade has been liberalized, the long-term savings of private enterprises have been released, creating a huge export drive.
Highlights in various fields China's pharmaceutical products are fully involved in international trade and full exchange. Last year, China continued to fully participate in worldwide exchanges in pharmaceutical economy, technology, and trade. Chinese companies are increasingly participating in various international pharmaceutical and medical equipment exhibitions held around the world. The stronger. From January to November of 2006, China's pharmaceutical and health products exports to Asia, Europe, North America and other markets were respectively 7.139 billion U.S. dollars, 4.979 billion U.S. dollars and 3.816 billion U.S. dollars, up by 27.73%, 27.06%, and 20.71% respectively; The African and Latin American markets have achieved good results. Exports were 572 million U.S. dollars and 1.40 billion U.S. dollars, up 38.57% and 38.79% year-on-year, respectively; exports to the United States exceeded the 3 billion U.S. dollar mark for the first time, reaching 3.597 billion U.S. dollars. The year-on-year increase was 20.76%.
Chemical raw materials continue to maintain its advantages. China's chemical raw material medicines have the characteristics of large scale, low cost, and high output. The export value has always accounted for about 50% of China's total exports of pharmaceutical and health products, and it is the export pillar of China's pharmaceutical and health products industry. Last year, China continued to maintain its advantages in the traditional bulk chemical raw materials, especially antibiotics, vitamins, hormones, antipyretic analgesics, amino acids, alkaloids and other products continue to occupy a considerable share in the international pharmaceutical market. Some companies that have obtained US FDA certification and EU COS certificates have also performed better in the market, and export prices have also steadily increased, such as terramycin, griseofulvin, gentamycin sulfate, and some companies. Vermectin, caffeine, etc. From January to November of 2006, China's export of chemical raw materials was 9.632 billion U.S. dollars, an increase of 25.84% year-on-year, accounting for 54.09% of China's total exports of pharmaceutical and health products.
Grabbing imitation and commission processing gradually become a trend, a number of companies have access to Europe and the United States high-end market pass. In 2006, it was the peak period for many “bombshell†proprietary drugs with sales exceeding US$500 million. The non-patented drug market emerged in an unexpectedly high number, which also made the market for contract outsourcing production and outsourcing more demanding. This is a domestic enterprise. Bring new opportunities for development. Some domestic companies prepare for the expiration of patent drugs 3 to 5 years in advance, and rank among the top suppliers of generic drugs for the first time.
Chemicals exports have made breakthroughs. In 2006, two more companies in China had obtained cGMP certification from EU countries, resulting in five certified companies. Their pharmaceutical products can already be exported to the EU high-end market. In addition, there are two other companies that have signed cooperation agreements with U.S. companies to sell productions that meet the US FDA requirements to European and American markets. The pace of production companies entering the generic drug market has strongly promoted the export of chemical agents. From January to November 2006, the export value of chemical preparations in China was 456 million U.S. dollars, an increase of 24.37% year-on-year.
The deficit in medical device exports has been reversed. For a long time, China’s foreign trade in medical devices has presented a serious trade deficit, with imports exceeding exports. However, with the continuous improvement of China’s medical device production technology and product quality in recent years, the demand for imported medical devices has begun to slow down, and the import of medical devices has exceeded exports. The situation has been fundamentally reversed. According to customs statistics, from January to November 2006, China's medical device export volume was 6.265 billion U.S. dollars, an increase of 29.42% year-on-year, and the growth rate of exports was much higher than that of imports by 26.54 percentage points. The surplus amounted to 2.923 billion U.S. dollars, and it continued to expand.
From the perspective of export product structure, small and medium-sized products such as conventional equipment, surgical instruments, and massage instruments have price advantages, and their functions and reliability are comparable to those of similar foreign products. For example, thermometers produced in Shenzhen account for 70% of the world's total, and 80% of French and German dentures are made in China. Therefore, China's small and medium-sized medical devices have obvious comparative advantages and competitiveness in the international market. In the export of high-tech medical equipment, some private high-tech enterprises in China have developed rapidly in recent years. Ultrasound diagnostic instruments and patient monitors have independent intellectual property rights and independent brands.
Some companies' medical device products have obtained CE certification and ISO13485 system certification, and they have access to the international market and can enter more international markets. The ability of the international market to purchase these products is significantly higher than that of other products, and after the products have obtained CE certification, the standards have become higher, they have become guaranteed products, and prices have increased a lot. In particular, EU customers attach great importance to CE certification. CE certification products will soon be able to enter European and American sales channels, shortening the transaction cycle. The EU Dual Directives (WEEE and RoHS) have little impact on the export of these products. Many companies are already well prepared to conduct special training on upstream suppliers and the products can meet the requirements of the directive.
The export of Chinese medicine exceeded the one billion US dollar mark for the first time. From January to November 2006, China’s export volume of Chinese medicines was US$985 million. Based on the monthly average value, exports of Chinese medicines for the whole year of 2006 will exceed US$1.07 billion, exceeding the US$1 billion mark for the first time, and exports of all kinds of bulk medicinal materials are presented. Sharply rising trend. Despite the negative reports on traditional Chinese medicines in the European market and the imminent transition period stipulated in the EU's Traditional Herbal Registration Directive, with the continued recognition of Chinese medicine products by Europeans, Chinese medicine exports to Europe have shown rapid growth, especially Exports from France, the Netherlands, the United Kingdom and Spain increased by more than 40%, and the Netherlands reached 75.25%.
Coexistence of Opportunities and Challenges In 2007, the foreign trade of China's pharmaceutical and healthcare products will continue to maintain rapid growth. Chemical raw material medicine is the export pillar of China's pharmaceutical and health care products industry. Continued expansion of chemical raw material medicines in 2007 is an inevitable choice. China will continue to maintain its advantages in traditional bulk chemical raw material medicines, especially antibiotics, vitamins, hormones, and solutions. Thermal analgesics, amino acids, alkaloids and other products will continue to occupy a considerable share of the world.
While maintaining comparative advantages and competitiveness in the export of small and medium-sized medical devices, some high-tech medical equipment products and high value-added products will grow steadily, which will enable China's medical devices to have greater room for development in the international market. It is expected that the growth in the number and value of imported medical devices will continue to slow in 2007, and the prices of some imported medical devices will decline.
Exports of Chinese medicines will continue to maintain a good momentum of rapid growth, and exports of Chinese herbal medicines, decoction pieces, extracts and health products will continue to grow rapidly. Although the proportion of Chinese patent medicines representing the essence of traditional Chinese medicine is still relatively small, with the increase of national policy support and the accumulation of international experience, Chinese patent medicines will be a new growth point for Chinese medicine exports.
This year marks the sixth year of China’s accession to the WTO. To promote the advancement of science and technology in the pharmaceutical industry and enhance its international competitiveness, all ministries and commissions of the country will continue to introduce a series of policies to advance the system from the technical and regulatory levels in order to support the pharmaceutical companies to go global. Recently, the Ministry of Commerce awarded the China Chamber of Commerce for the Import and Export of Medicines and Health Products to set up an Export Commodity Technical Service Center. The center mainly studies the problems faced by international registration of enterprises and guides enterprises in the international registration of pharmaceuticals. This is to expand the export of medicines and health products in China. Will play an important role in promoting.
While optimistic expectations, some factors that affect export growth can not be ignored. The appreciation of the renminbi will weaken the competitiveness of Chinese medicine and health products in the international market. The increase in labor costs and raw material prices continue to rise sharply. The tight supply of coal, electricity, oil and transportation will affect the normal production and contractual performance of enterprises. Although trade protectionism is not the mainstream, trade friction problems have become increasingly prominent and the forms of friction have become increasingly diversified. In addition, the EU has introduced a series of related regulations such as EUP, which have increased the uncertainties in the export of Chinese medicine and health products.
At present, China’s foreign exchange reserves have exceeded one trillion U.S. dollars, and the macro environment has undergone fundamental changes. In accordance with the requirements of the Ministry of Commerce, lowering the trade surplus and adjusting the product mix will become the main tasks for the import and export of medical and health products this year.
In view of the high base in 2006, it also made it increasingly difficult for China's foreign trade in medical and health products to maintain rapid growth in 2007. It is expected that the import and export of Chinese medicine and health products will still be expected to maintain an increase of more than 15% in 2007, and the total import and export volume will exceed 350. One hundred million U.S. dollars.
Concentric Reduver, Eccentric Reducer
Material
Carbon Steel like A234 WPB, 20G, A105, Q235A/B and alloy steel like ASTM A234 WP5, WP11, WP12
Executive Standard
ASME B 16.9, DIN, JIS, BS, etc
Size
1/2"-24"
Wall Thickness
SCH10~SCH160, STD, XS, XXS
Type
Seamless
Welding Method
Butt Welding
Surface Treatment
grit blasting, black or transparent painting or according to the requirement of client
Packing
Dyrable wooden pallet or wooden case or according to the requirement of client
Stainless Steel Reducer, Carbon Steel Reducer, Butt-Weld Reducer, Stainless Steel Concentric Reducer
Cangzhou Weiheng Pipe Industry Co.,Ltd , https://www.czweiheng.com